Stock Price

A NASDAQ-listed firm merges with a blockchain powerhouse, signaling a major shift for real-world asset tokenization and the future of finance.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

The company reports a banner year with doubled free cash flow and EPS, launching a new $200M share buyback and signaling strong future growth.

As population growth in high-risk areas drives storm damage to new records, experts reveal science-backed home upgrades that can save your property.

Restaurant Brands International reports strong 2025 results, fueled by booming international sales, but faces headwinds with Popeyes' slump and BK franchisee pressures.

Dana Inc. names Byron Foster its next CEO, signaling a focus on growth and continuity as R. Bruce McDonald remains Chairman amid a major industry shift.

The newly rebranded firm touts record fundraising and a key acquisition, but declining non-GAAP earnings reveal a more complicated financial reality for investors.

The Chinese education firm is back in the NYSE's good graces, but a 12-month review period means the real test of stability has just begun.

Aircraft leasing giant Avolon posts record profits, capitalizing on soaring travel demand and severe aircraft shortages plaguing global airlines.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

Nektar Therapeutics secures a massive $400M offering, signaling strong investor faith in its lead drug, rezpegaldesleukin, for autoimmune diseases.

Gabelli Multimedia Trust maintains its high-yield distribution after a blockbuster 2025, but what does its 21% 'cash on cash' payout really mean for investors?

The insurer's double-digit dividend hike follows a year of record core earnings, rewarding shareholders and showcasing its robust financial health.

The satellite firm unveils a complex debt shuffle and $1B capital raise, fueling its network vision while sending its stock tumbling on dilution fears.

Grid Dynamics' new 'Preferred Vendor' status with a top cloud provider validates its role in solving the complex engineering challenges of enterprise AI.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

Indoor ag firm Local Bounti faces a potential NYSE delisting for the second time, highlighting severe financial pressures in the high-tech farming sector.

Lincoln International data reveals slowing growth and rising debt distress in private companies, a stark contrast to the heated M&A market for top assets.

The energy giant's dividend increase to $1.27 reflects robust financial health, strategic pivots to renewables, and a strong commitment to shareholders.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?